An oft-repeated message is that primary aldosteronism is not rare; it is quite common. An equally urgent message is that ...

Merck & Co. has won U.S. Food and Drug Administration priority review for its application seeking expanded use of its Welireg oral cancer drug in patients with rare tumors that form in and around the ...

A brain tumor is a mass of abnormal cells that grow in the brain. Brain tumors can be benign (non-cancerous) or malignant (cancerous) and can start anywhere in the brain. Malignant tumors grow rapidly ...

When a child develops a brain tumor, early diagnosis is essential. Alan Cohen, M.D., director of pediatric neurosurgery at Johns Hopkins Children’s Center, shares the most common signs and symptoms ...

The tissue adjacent to a tumor behaves differently than areas farther away: The tumor’s cancerous cells influence their surroundings, blocking the body’s immune defenses and creating a sort of haven ...

Brain cancer and other nervous system cancers have a 33.4% five-year survival rate. In adults, brain tumors rarely begin in the brain — when they do, they're known as primary brain cancers.

For 3 out of every hundred people with cancer, the primary site of cancer isn't found. When this is the case, the tumor is usually referred to as a metastatic cancer of unknown primary origin. With ...

Chimeric antigen receptor-T (CAR-T) cell therapy, initially successful in hematologic malignancies, presents a promising avenue for treating solid tumors, including CRC. This review explores the ...

When you multiply by 1 the answer stays the same. 21 × 1 = 21 When you multiply by 10, move all the digits one place to the left, putting a zero in the empty space. 21 × 10 = 210 When you ...

Adrenal glands, responsible for producing hormones that manage the body’s stress response, can sometimes become overburdened. This can result in a commonly seen condition called adrenal fatigue ...

Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International ...